Sanofi to acquire Vicebio for $1.6bn.

Sanofi, a French multinational pharmaceutical and healthcare company, agreed to acquire Vicebio, a biopharmaceutical company, for $1.6bn. "Vicebio and its incredibly passionate team have been driven by the ambition to develop next-generation vaccines aimed at targeting multiple life-threatening respiratory viruses simultaneously. This acquisition validates our ability to combine innovation and deep scientific expertise towards a common goal of advancing public health prevention, and we're excited to enter the next chapter to accelerate the global impact of our work," Emmanuel Hanon, Vicebio CEO.